Affiliation:
1. National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4255
Abstract
ABSTRACT
To understand the mechanism of retinoid resistance, we studied the subcellular localization and function of retinoid receptors in human breast cancer cell lines. Retinoid X receptor α (RXRα) localized throughout the nucleoplasm in retinoid-sensitive normal human mammary epithelial cells and in retinoid-responsive breast cancer cell line (MCF-7), whereas it was found in the splicing factor compartment (SFC) of the retinoid-resistant MDA-MB-231 breast cancer cell line and in human breast carcinoma tissue. In MDA-MB-231 cells, RXRα was not associated with active transcription site in the presence of ligand. Similarly, ligand-dependent RXR homo- or heterodimer-mediated transactivation on RXR response element or RARE showed minimal response to ligand in MDA-MB-231 cells. Infecting MDA-MB-231 cells with adenoviral RXRα induced nucleoplasmic overexpression of RXRα and resulted in apoptosis upon treatment with an RXR ligand. This suggests that nucleoplasmic RXRα restores retinoid sensitivity. Epitope-tagged RXRα and a C-terminus deletion mutant failed to localize to the SFC. Moreover, RXRα localization to the SFC was inhibited with RXRα C-terminus peptide. This peptide also induced ligand-dependent transactivation on RXRE. Therefore, the RXRα C terminus may play a role in the intranuclear localization of RXRα. Our results provide evidence that altered localization of RXRα to the SFC may be an important factor for the loss of retinoid responsiveness in MDA-MB-231 breast cancer cells.
Publisher
American Society for Microbiology
Subject
Cell Biology,Molecular Biology
Reference57 articles.
1. Bischoff, E. D., M. M. Gottardis, T. E. Moon, R. A. Heyman, and W. W. Lamph. 1998. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res. 58 : 479-484.
2. Boccardo, F., L. Canobbio, M. Resasco, A. U. Decensi, G. Pastorino, and F. Brema. 1990. Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer. J. Cancer Res. Clin. Oncol. 116 : 503-506.
3. Cassidy, J., M. Lippman, A. Lacroix, and G. Peck. 1982. Phase II trial of 13-cis-retinoic acid in metastatic breast cancer. Eur. J. Cancer Clin. Oncol. 18 : 925-928.
4. Castelein, H., P. E. Declercq, and M. Baes. 1997. DNA binding preferences of PPAR alpha/RXR alpha heterodimers. Biochem. Biophys. Res. Commun. 233 : 91-95.
5. Chen, A. C., X. Guo, F. Derguini, and L. J. Gudas. 1997. Human breast cancer cells and normal mammary epithelial cells: retinol metabolism and growth inhibition by the retinol metabolite 4-oxoretinol. Cancer Res. 57 : 4642-4651.
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献